Cost of Soliris drug will impact other areas of health service, says HSE chief

The head of the HSE has admitted that the rest of the health service will have to suffer because of a decision to pay for expensive drugs for two patients with a rare blood disorder.

The head of the HSE has admitted that the rest of the health service will have to suffer because of a decision to pay for expensive drugs for patients with a rare blood disorder.

Tony O'Brien said that the cost of the Soliris drug - which costs €430,000 a year for every patient - will lead to cuts elsewhere in the service.